MT1

10mg / Vial

£20.00

MT1

£20.00

Third-party tested

1–2 day tracked dispatch

Discreet packaging

99%+ purity guaranteed

For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.

Reconstitution

Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.

Swab both vial stoppers with alcohol and allow to dry.
Draw the required volume of bacteriostatic water with a sterile syringe.
Add the water slowly down the inside wall of the vial — never directly onto the powder.
Swirl gently until fully dissolved. Never shake.
Confirm the solution is clear and particle-free.
Label with date and concentration, then refrigerate at 2–8 °C.

Full guide & dose calculator

Storage & Handling

Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.

Quality & Shipping FAQ

Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.

View the peer-reviewed research

Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

Melanotan I (MT1)

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone and a selective agonist of the MC1R melanocortin receptor. It is used as a reference compound in melanocortin-system research.

About the compound

Melanotan I has been studied in published research for its selective interaction with the MC1R receptor — part of the melanocortin receptor family that remains an active subject of laboratory research.

Specifications

Purity: 99%+ (third-party verified)
Independently tested before dispatch
Presented as lyophilised (freeze-dried) powder
Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.

Afamelanotide (MT1) Skin & Pigmentation Phase 3 RCT

Afamelanotide Phase 3: Six-Fold Increase in Sun Exposure Tolerance — Clinically Approved

New England Journal of Medicine · Langendonk et al., 2015

A Phase 3 RCT in 74 patients with erythropoietic protoporphyria demonstrated afamelanotide produced a median six-fold increase in direct sunlight exposure tolerated vs placebo, alongside significant reductions in phototoxic pain. The mechanistic basis is potent stimulation of eumelanin synthesis providing a physical UV barrier. These results supported approval by the EMA (2014) and FDA (2019) of afamelanotide (Scenesse) for EPP.

Phase 3 RCT EMA + FDA Approved Eumelanin

Melanocortin (α-MSH) Skin & Pigmentation Human RCT

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine · Langendonk et al., 2015

Two randomised placebo-controlled trials (168 patients) of afamelanotide, an α-melanocyte-stimulating-hormone (α-MSH) analogue from the same melanocortin family as Melanotan compounds. Subcutaneous implants increased eumelanin-based photoprotection, significantly extending pain-free sunlight exposure and reducing phototoxic reactions, with improved quality of life. Adverse events were mostly mild.

Melanocortin Agonist Melanogenesis Human RCT

View the full research library →